Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.

[1]  S. Inoue,et al.  Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. , 2010, Ophthalmology.

[2]  Y. Tano,et al.  One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. , 2010, Ophthalmology.

[3]  K. Freund,et al.  Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. , 2009, American journal of ophthalmology.

[4]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy , 2009, Eye.

[5]  I. Chowers,et al.  Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel , 2008, Molecular vision.

[6]  F. Parmeggiani,et al.  Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[7]  S. Fisher,et al.  Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA , 2008, Nature Genetics.

[8]  A. Luff,et al.  An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment , 2008, Eye.

[9]  F. Parmeggiani,et al.  Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration , 2007, Pharmacogenetics and genomics.

[10]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[11]  S. Yoneya,et al.  Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. , 2007, Investigative ophthalmology & visual science.

[12]  P. Tommila,et al.  The Effect of Complement Factor H Y402H Polymorphism on the Outcome of Photodynamic Therapy in Age-related Macular Degeneration , 2007, European journal of ophthalmology.

[13]  Gonçalo R. Abecasis,et al.  A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration , 2007, Proceedings of the National Academy of Sciences.

[14]  I. Maruko,et al.  Clinical characteristics of exudative age-related macular degeneration in Japanese patients. , 2007, American journal of ophthalmology.

[15]  Y. Tano,et al.  Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy , 2007, British Journal of Ophthalmology.

[16]  F. Wen,et al.  Subtype lesions of neovascular age-related macular degeneration in Chinese patients , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[17]  M. Mandai,et al.  HEMORRHAGIC COMPLICATIONS AFTER PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY , 2007, Retina.

[18]  N. Camp,et al.  A Variant of the HTRA1 Gene Increases Susceptibility to Age-Related Macular Degeneration , 2006, Science.

[19]  C. Barnstable,et al.  HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration , 2006, Science.

[20]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[21]  R. Ritch,et al.  Ethnic variation in AMD‐associated complement factor H polymorphism p.Tyr402His , 2006, Human mutation.

[22]  Yun Li,et al.  CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration , 2006, Nature Genetics.

[23]  Johanna M Seddon,et al.  Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration , 2006, Nature Genetics.

[24]  J. Haines,et al.  Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. , 2006, American journal of human genetics.

[25]  Y. Tano,et al.  Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West , 2006, Japanese Journal of Ophthalmology.

[26]  S. Fisher,et al.  Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk , 2005 .

[27]  G. Abecasis,et al.  Meta-analysis of genome scans of age-related macular degeneration. , 2005, Human molecular genetics.

[28]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Gilbert,et al.  Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration , 2005, Science.

[30]  J. Ott,et al.  Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.

[31]  T. Lai,et al.  Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.

[32]  Haitao Li,et al.  Polypoidal choroidal vasculopathy in elderly Chinese patients , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  M. Moschos,et al.  Polypoidal choroidal vasculopathy and exudative age-related macular degeneration in Greek population , 2004, Eye.

[34]  T. Peto,et al.  The epidemiology of age-related macular degeneration. , 2004, American journal of ophthalmology.

[35]  G. Abecasis,et al.  Age-Related Macular Degeneration: A High-Resolution Genome Scan for Susceptibility Loci in a Population Enriched for Late-Stage Disease , 2004 .

[36]  N. Bressler.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. , 2003, American journal of ophthalmology.

[37]  M. Matsumura,et al.  Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. , 2003, Archives of ophthalmology.

[38]  S. Santangelo,et al.  A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. , 2003, American journal of human genetics.

[39]  T. Matise,et al.  Age-related macular degeneration--a genome scan in extended families. , 2003, American journal of human genetics.

[40]  A. Bird,et al.  Towards an understanding of age-related macular disease , 2003, Eye.

[41]  M. Blumenkranz,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. , 2002, Archives of ophthalmology.

[42]  N. Bressler.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .

[43]  B. Lafaut,et al.  Polypoidal choroidal vasculopathy in Caucasians , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[44]  D. Weeks,et al.  A full genome scan for age-related maculopathy. , 2000, Human molecular genetics.

[45]  P. Courtright,et al.  Age-related macular degeneration in Chinese-Canadians. , 1999, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[46]  T. Matise,et al.  Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. , 1998, Archives of ophthalmology.

[47]  G. Naumann.  The Bowman Lecture , 1995, Eye.

[48]  Mark Michels,et al.  Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.

[49]  I. Georgalas,et al.  Retinal hemorrhage after photodynamic therapy in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[50]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.